IP Lawsuits Settled

Two lawsuits against prominent researcher Craig Thompson for allegedly failing to share intellectual property with his institution lead to a licensing agreement on cancer diagnostics.

By | September 5, 2012

Brian Turner" > Flickr, Brian Turner

In December 2011, the Leonard and Madlyn Abramson Family Cancer Research Institute, part of the Abramson Cancer Center of the University of Pennsylvania, filed a $1 billion lawsuit against its former head Craig Thompson, who at that time had moved on to become the president of Memorial Sloan-Kettering Cancer Center in New York City. Two months later, in February 2012, the University of Pennsylvania filed a second lawsuit.

Both lawsuits revolved around Thompson’s alleged secrecy regarding his involvement in the biotech company Agios Pharmaceuticals (a co-defendant in both suits) and business deals he was making based on his research on cancer cell metabolism.

The terms of the new settlement are “hazy,” ScienceInsider reported, but one known outcome is a licensing agreement between Agios and Penn involving diagnostics that measure metabolism of certain cancers.

“We are pleased to be collaborating with Penn and value the contributions of their scientists to this exciting field,” Agios Chief Executive Officer David Schenkein said in a press release. “We are excited to now focus on the most important task of all—transforming the lives of cancer patients.”

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Genetic Test Solves Royal Mystery
    Notebook Genetic Test Solves Royal Mystery

    Genetic analyses lay to rest conspiracy theories about death of Belgian King Albert I, who lost his life in a rock climbing accident more than 80 years ago.

  2. Investigation Finds Pathologist Guilty of Systemic Misconduct
  3. Bacteria and Humans Have Been Swapping DNA for Millennia
  4. Curious George
    The Scientist Curious George

    George Church has consistently positioned himself at genomics’ leading edge.